Financial StabilityArcturus Therapeutics Holdings Inc. has extended their cash runway, indicating a stable financial position that supports ongoing operations and development efforts.
Innovation And TechnologyArcturus Therapeutics is advancing with a proprietary lipid nanoparticle delivery platform which aids cellular uptake of their therapeutic agents, offering enhanced delivery and potentially improving therapeutic outcomes.
Product PipelineArcturus Therapeutics is making strides in developing therapeutics for vaccines and rare diseases, with the first ever self-amplifying mRNA vaccine, Kostaive, already on the market in Japan.